Baker Bros. Advisors LP Glycomimetics Inc Transaction History

Baker Bros. Advisors LP

  • $9.34 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Nov 14, 2018
SELL
$13.7 - $17.12 $3.99 Million - $4.99 Million
-291,214 Closed
0 $0
Q2 2018

Aug 14, 2018
SELL
$14.63 - $19.19 $3.98 Million - $5.22 Million
-272,098 Reduced 48.3%
291,214 $4.7 Million
Q3 2017

Nov 14, 2017
BUY
$10.14 - $14.85 $5.71 Million - $8.37 Million
563,312
563,312 $7.88 Million

Others Institutions Holding GLYC

# of Institutions
34
Shares Held
17.8M
Call Options Held
0
Put Options Held
0
View Full List

About GLYCOMIMETICS INC

GLYC Quotes by TradingView
  • Ticker GLYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,423,900
  • Market Cap $22M
  • Description
  • GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...
More about GLYC
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email